In subclinical AF, apixaban reduced stroke or systemic embolism but increased major bleeding vs. aspirin at 3.5 y

Ilya Y Shadrin; L Kristin Newby

doi:10.7326/J24-0002

In subclinical AF, apixaban reduced stroke or systemic embolism but increased major bleeding vs. aspirin at 3.5 y

Ann Intern Med. 2024 Mar;177(3):JC26. doi: 10.7326/J24-0002. Epub 2024 Mar 5.

Authors

Ilya Y Shadrin¹, L Kristin Newby¹

Affiliation

¹ Duke University School of Medicine, Durham, North Carolina, USA (I.Y.S., L.K.N.).

PMID: 38437696
DOI: 10.7326/J24-0002

Abstract

Healey JS, Lopes RD, Granger CB, et al; ARTESIA Investigators. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2024;390:107-117. 37952132.

MeSH terms

Anticoagulants / adverse effects
Aspirin / adverse effects
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Embolism* / prevention & control
Hemorrhage / chemically induced
Humans
Pyrazoles*
Pyridones*
Stroke* / prevention & control
Treatment Outcome

Substances

Aspirin
apixaban
Anticoagulants
Pyrazoles
Pyridones